10P Phase I study of magrolimab (ONO-7913) and nivolumab (ONO-4538, NIV) in combination with FOLFOX and bevacizumab (Bev) or cetuximab (Cet) as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer (CRC)K. Yamaguchi, T. Yoshino, S. Boku et al.|Annals of Oncology|2025Cited by 2